ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong · Delayed Price · Currency is HKD 4.580
+0.150 (3.39%)
Feb 13, 2026, 4:08 PM HKT
HKG:1541 Revenue
ImmuneOnco Biopharmaceuticals (Shanghai) had revenue of 44.01M CNY in the half year ending June 30, 2025, with 3,815.84% growth. This brings the company's revenue in the last twelve months to 122.83M, up 1,584.92% year-over-year. In the year 2024, ImmuneOnco Biopharmaceuticals (Shanghai) had annual revenue of 79.54M with 933.61% growth.
Revenue (ttm)
122.83M CNY
Revenue Growth
+1,584.92%
P/S Ratio
14.68
Revenue / Employee
629.90K CNY
Employees
195
Market Cap
1.98B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 79.54M | 71.84M | 933.61% |
| Dec 31, 2023 | 7.70M | 2.01M | 35.24% |
| Dec 31, 2022 | 5.69M | -8.12M | -58.79% |
| Dec 31, 2021 | 13.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full Definition